GlobeNewswire: Reata Pharmaceuticals, Inc. Contains the last 10 of 120 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T10:47:36ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2021/06/07/2243031/0/en/Reata-Pharmaceuticals-Announces-Participation-in-The-Goldman-Sachs-42nd-Annual-Global-Healthcare-Conference.html?f=22&fvtc=4&fvtv=28818Reata Pharmaceuticals Announces Participation in The Goldman Sachs 42nd Annual Global Healthcare Conference2021-06-07T17:30:00Z<![CDATA[PLANO, Texas, June 07, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that management will participate in a virtual Fireside chat and hold 1x1 meetings at the Goldman Sachs 42nd Annual Global Healthcare Conference on Tuesday, June 8, 2021.]]>https://www.globenewswire.com/news-release/2021/05/19/2232302/0/en/Reata-Announces-that-The-FDA-Has-Asked-The-Company-to-Request-a-Pre-NDA-Meeting-for-Omaveloxolone-for-the-Treatment-of-Friedreich-s-Ataxia.html?f=22&fvtc=4&fvtv=28818Reata Announces that The FDA Has Asked The Company to Request a Pre-NDA Meeting for Omaveloxolone for the Treatment of Friedreich’s Ataxia2021-05-19T10:45:00Z<![CDATA[PLANO, Texas, May 19, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that it received a communication from the Division of Neurology Products 1 (“Division”) of the U.S. Food and Drug Administration (“FDA”) stating that, after a preliminary review of briefing materials for an upcoming Type C meeting, a pre-NDA meeting is the most appropriate format for a discussion of the development program for omaveloxolone in Friedreich’s ataxia (“FA”). The Division suggested that the Company withdraw the current meeting request for a Type C meeting and instead request a pre-NDA meeting, which the Division will grant upon receipt. The Division asked the Company to focus the new briefing package on questions, issues, and needs applicable to a pre-NDA meeting. As requested by the FDA, the Company plans to withdraw the current request for a Type C meeting and submit a request for a pre-NDA meeting as soon as practicable.]]>https://www.globenewswire.com/news-release/2021/05/06/2224272/0/en/Reata-Pharmaceuticals-Inc-Announces-First-Quarter-2021-Financial-Results-and-Provides-an-Update-on-Clinical-Development-Programs.html?f=22&fvtc=4&fvtv=28818Reata Pharmaceuticals, Inc. Announces First Quarter 2021 Financial Results and Provides an Update on Clinical Development Programs2021-05-06T10:45:00Z<![CDATA[ANNOUNCES FDA ACCEPTED FOR FILING REATA’S NDA OF BARDOXOLONE FOR THE TREATMENT OF PATIENTS WITH CKD CAUSED BY ALPORT SYNDROME]]>https://www.globenewswire.com/news-release/2021/05/03/2221200/0/en/Reata-Pharmaceuticals-Announces-Presentations-at-Upcoming-Investor-Conferences.html?f=22&fvtc=4&fvtv=28818Reata Pharmaceuticals Announces Presentations at Upcoming Investor Conferences2021-05-03T10:45:00Z<![CDATA[PLANO, Texas, May 03, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that management will present and hold 1x1 meetings at the following investor conferences:]]>https://www.globenewswire.com/news-release/2021/04/28/2219140/0/en/Reata-Pharmaceuticals-Inc-To-Report-First-Quarter-2021-Financials-and-To-Provide-an-Update-on-Development-Programs-on-May-6-2021.html?f=22&fvtc=4&fvtv=28818Reata Pharmaceuticals, Inc. To Report First Quarter 2021 Financials and To Provide an Update on Development Programs on May 6, 20212021-04-28T21:00:00Z<![CDATA[PLANO, Texas, April 28, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced that it will report financial results and provide an update on recent progress on its development programs pre-market on May 6, 2021.]]>https://www.globenewswire.com/news-release/2021/04/26/2217232/0/en/Reata-Announces-FDA-Accepted-for-Filing-the-NDA-for-Bardoxolone-for-the-Treatment-of-Patients-With-Chronic-Kidney-Disease-Caused-by-Alport-Syndrome.html?f=22&fvtc=4&fvtv=28818Reata Announces FDA Accepted for Filing the NDA for Bardoxolone for the Treatment of Patients With Chronic Kidney Disease Caused by Alport Syndrome2021-04-26T20:54:15Z<![CDATA[Approximately 30,000-60,000 Patients in the United States Are Affected With Alport Syndrome, a Life-Threatening Disease With No Approved Therapies]]>https://www.globenewswire.com/news-release/2021/04/15/2210616/0/en/Reata-Announces-the-Appointments-of-Christy-J-Oliger-and-Shamim-Ruff-to-Its-Board-of-Directors.html?f=22&fvtc=4&fvtv=28818Reata Announces the Appointments of Christy J. Oliger and Shamim Ruff to Its Board of Directors2021-04-15T10:45:00Z<![CDATA[PLANO, Texas, April 15, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced the appointments of Christy J. Oliger and Shamim Ruff to its Board of Directors, effective April 15, 2021.]]>https://www.globenewswire.com/news-release/2021/03/29/2201131/0/en/Reata-Pharmaceuticals-Announces-Presentations-at-Upcoming-Medical-Conferences.html?f=22&fvtc=4&fvtv=28818Reata Pharmaceuticals Announces Presentations at Upcoming Medical Conferences2021-03-29T21:34:48Z<![CDATA[PLANO, Texas, March 29, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that abstracts highlighting clinical data for bardoxolone methyl (“bardoxolone”) will be presented at two upcoming nephrology conferences including The World Congress of Nephrology 2021 being held virtually from April 15 – 19, 2021 and the 58th European Renal Association and European Dialysis and Transplant Association (“ERA-EDTA”) Congress being held from June 5 – 8, 2021 in Berlin, Germany and virtually.]]>https://www.globenewswire.com/news-release/2021/03/01/2184053/0/en/Reata-Pharmaceuticals-Inc-Announces-Fourth-Quarter-and-Full-Year-2020-Financial-Results-and-Provides-an-Update-on-Clinical-Development-Programs.html?f=22&fvtc=4&fvtv=28818Reata Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2020 Financial Results and Provides an Update on Clinical Development Programs2021-03-01T11:35:00Z<![CDATA[ANNOUNCES FIRST NDA SUBMISSION FOR COMPANY’S LEAD PROGRAM: BARDOXOLONE IN ALPORT SYNDROME]]>https://www.globenewswire.com/news-release/2021/03/01/2184047/0/en/Reata-Pharmaceuticals-Inc-Submits-NDA-for-Company-s-Lead-Program-Bardoxolone-in-Alport-Syndrome.html?f=22&fvtc=4&fvtv=28818Reata Pharmaceuticals, Inc. Submits NDA for Company’s Lead Program: Bardoxolone in Alport Syndrome2021-03-01T11:30:00Z<![CDATA[PLANO, Texas, March 01, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that it has submitted a New Drug Application (“NDA”) for bardoxolone methyl (“bardoxolone”) for the treatment of chronic kidney disease (“CKD”) caused by Alport syndrome to the U.S. Food and Drug Administration (“FDA”).]]>